Middle East Pharmaceutical Industries Company

4016.SRSAUHealthcare● Active

$62.10

$-0.20(-0.32%)

Market Cap$2.2B

P/E Ratio—

52W High$79.08572

52W Low$53.88572

Avg Volume188K

Open$62.40

Beta0.48

Net Income Financials Revenue

Middle East Pharmaceutical Industries Company (4016.SR) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

4016.SR · net income · updated Jun 15, 2026

Core profitability metrics

4016.SR · net income · margin · TTM · CAGR

Net income was $97.0M for FY2025 (fiscal year ending 2025-12-31), up 21.5% year-over-year. Net profit margin was 21.1%. Based on available data, Middle East Pharmaceutical Industries Company has been profitable since at least 2019.

FY2025 Net Income$97.0M▲ +21.5% YoY

Trailing 12M (TTM)$104.5Mtrailing 4 quarters sum

Net Profit Margin21.1%$97.0M ÷ $460.5M

YoY Change+21.5%—

5-Year CAGR+5.9%FY2020 → FY2025

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 15, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2019

▸ FMP /income-statement · Annual · 4016.SR net income history · 4016.SR profit margin

Annual net income data

4016.SR · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025$97.0M▲ +21.5%21.1%$460.5M

FY2024$79.8M▲ +21.3%20.3%$394.0M

FY2023$65.8M▲ +10.7%19.4%$338.4M

FY2022$59.5M▼ 10.3%19.6%$302.7M

FY2021$66.3M▼ 9.0%23.1%$287.2M

Net income vs peers (Healthcare)

4016.SR vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Middle East Pharmaceutical Industries CompanyYOU

4016.SR

$97.0M+21.5%21.1%

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Middle East Pharmaceutical Industries Company (4016.SR) reported net income of $97.0M for FY2025 (fiscal year ending 2025-12-31), up 21.5% year-over-year. The net profit margin was 21.1% — meaning the company kept $0.21 of every dollar of revenue as profit.

Based on available data, Middle East Pharmaceutical Industries Company has been profitable since at least 2019. Net income reached a peak of $97.0M in FY2025. Data available for 7 fiscal years.

Middle East Pharmaceutical Industries Company's net profit margin was 21.1% for FY2025, based on the latest annual results.

Investors sometimes search for "Middle East Pharmaceutical Industries Company net worth" — the company's market capitalization is a separate figure from 4016.SR net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

4016.SR net income · 5 questions

Middle East Pharmaceutical Industries Company is profitable. The company reported net income of $97.0M for FY2025, a net profit margin of 21.1%. Net income was up 21.5% year-over-year. Based on available data, Middle East Pharmaceutical Industries Company has been profitable since at least 2019.

is 4016.SR profitabledoes 4016.SR make a profit4016.SR profitability4016.SR profitable company

▸ Source: FMP /income-statement · GAAP · Middle East Pharmaceutical Industries Company · Middle East Pharmaceutical Industries Company SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026